what is in glp-1 patches - Weight Loss - DOT Drug Screenings & Wellness Testing Nashville GLP-1 Support Patch | GLP-1

The publication of standardized treatment guidelines in 2024 i.e., the 2024 Edition of the Clinical Guidelines for the Diagnosis and Treatment of Obesity (2024) formally endorsed GLP-1 therapies as a recommended option for weight management

View at Publisher | View at Google Scholar Smolen JS, Aletaha D

According to FDA prescribing information for Wegovy (semaglutide 2.4 mg), nausea occurs in approximately 44% of patients taking the medication for weight loss, while vomiting affects roughly 24% of users at the maintenance dose

*Indicates a required field

10.1111/adb.12583 27 HernandezN

However, continuing to track how employers and payers are navigating the complex environment around these drugs is key to ensuring they can reach the right patients